Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15695029 | 0.89 | HDAC1 (0.40) | HDAC1MAPTALDH1A1KDM4EAAK1 | |
| SCHEMBL13728497 | 0.82 | KDM4E (0.41) | HDAC1MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13728237 | 0.81 | MAPT (0.44) | MAPTKMT2AALDH1A1KDM4ENPC1 | |
| SCHEMBL22447781 | 0.81 | SMYD3 (0.43) | MAPTALDH1A1KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL31129277 | 0.77 | MAPT (0.46) | HDAC1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL20529712 | 0.74 | MAPT (0.44) | HDAC1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL16839826 | 0.72 | FPR2 (0.43) | MAPTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL15695016 | 0.70 | KDM4E (0.39) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL26291191 | 0.69 | CCR2 (0.39) | ALDH1A1SMYD3OPRM1OPRD1FPR2 | |
| SCHEMBL2761098 | 0.69 | FPR2 (0.57) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705039-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2705039-B1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9422292-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2705039-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151512-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151512-A2 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135316-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | HDAC1 14/4885MAPT 356/4885MEN1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.